Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 15/20 | 0.34 |
| ▸ | EED | O75530 | 1/20 | 0.33 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.33 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.33 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.33 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30242139 | 1.00 | ATR (0.39) | ATROPRK1EEDRBBP4SUZ12 | |
| SCHEMBL12818795 | 0.81 | HSP90AA1 (0.36) | USP30 | |
| SCHEMBL30521347 | 0.78 | OPRK1 (0.39) | OPRK1 | |
| SCHEMBL23800342 | 0.78 | OPRK1 (0.39) | OPRK1 | |
| SCHEMBL17113145 | 0.77 | KMT2A (0.39) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL12818333 | 0.74 | TTK (0.39) | — | |
| SCHEMBL21839894 | 0.73 | L3MBTL1 (0.38) | OPRK1USP30 | |
| SCHEMBL559566 | 0.73 | USP30 (0.38) | USP30 | |
| SCHEMBL29929897 | 0.73 | USP30 (0.38) | USP30 | |
| SCHEMBL24744896 | 0.72 | KDM4E (0.36) | ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348398-A1 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2023-11-02 | — | — | US | disclosed |
| EP-4136077-A1 | BENZIMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-02-22 | — | — | EP | disclosed |
| CN-115485266-A | Benzimidazole derivatives | 豪夫迈·罗氏有限公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2021209484-A1 | BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348398-A1 | Benzimidazole derivatives | HRH4, H1-4, CYP3A4 | ATR 2728/4885OPRK1 905/4885EED 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.